title: [Clinical study on antimicrobial prophylaxis following extracorporeal shock wave lithotripsy].
abstract: One hundred and sixty one patients with upper urinary stones were examined for antimicrobial prophylaxis following extracorporeal shock wave lithotripsy (ESWL). They were divided into two groups, the low-risk group (n = 133) and high-risk group (n = 28), according to the risk factors of urinary tract infection. The patients in the low-risk group were further randomized into two groups which were orally given ofloxacin for 7 days after ESWL (Group A, n = 66), no antimicrobial (Group B, n = 67). The patients in the high-risk group were randomly subdivided into three groups which were given flomoxef intravenously for 2 or 3 days and ofloxacin for 4 or 5 days thereafter (Group C, n = 10), flomoxef only for 2 or 3 days and no drugs later (Group D, n = 10), ofloxacin for 7 days (Group E, n = 8). In all of the patients in the low-risk group, during the 7 days after ESWL, fever elevation was observed in only 1.5% of patients, and bacteriuria in 10.0% on the 7th day. There was no difference in frequency of fever elevation and bacteriuria following ESWL between Group A and Group B. These findings indicate that prophylactic antimicrobial after ESWL treatment is not necessary for low risk patients with urinary tract infections. In the high-risk group, the over-all rates of fever elevation and bacteriuria were 21.4% and 24.0% respectively. The difference of effectiveness among the prophylactic regimens of the three groups (Group C, D, E) was not shown.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Urology, Wakayama Medical College.
authors.forename: S
authors.initials: S
authors.lastname: Morimoto
authors.forename: A
authors.initials: A
authors.lastname: Hirano
authors.forename: T
authors.initials: T
authors.lastname: Ohkawa
authors.forename: J
authors.initials: J
authors.lastname: Doi
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Hagino
authors.forename: S
authors.initials: S
authors.lastname: Kitamura
authors.forename: Y
authors.initials: Y
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: Y
authors.initials: Y
authors.lastname: Miyazaki
mesh_terms: D000328:Adult; D001437:Bacteriuria; D002511:Cephalosporins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D011292:Premedication; D015607:Stents; D014545:Urinary Calculi / Q000628:therapy*; D014552:Urinary Tract Infections / Q000517:prevention & control*
chemical_list: D002511:Cephalosporins; D015242:Ofloxacin; C045693:flomoxef